Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Exclusion Criteria

• •1\. Patients with evidence of myelopathy or demyelination of central nerve
• •2\. Patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes（diabetic neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy）
• •3\. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, malignancy, vasculitis, Crow-Fukase syndrome, Sjögren syndrome.
• •4\. Patients with multifocal motor neuropathy.
• •5\. Patients treated with plasmapheresis at 3 months before informed consent.
• •6\. Patients treated with rituximab at 6 months before informed consent.
• •7\. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.
• •8\. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.
• •9\. Patients with history of shock or hypersensitivity for NPB-01.
• •10\. Patients with IgA deficiency.
• •11\. Patients with malignancy at informed consent.
• •12\. Patients with impaired liver function.
• •13\. Patients with impaired renal function.
• •14\. Patients with cerebro- or cardiovascular disorders.
• •15\. Patients with high risk of thromboembolism.
• •16\. Patients with hemolytic/hemorrhagic anemia.
• •17\. Patients with decreased cardiac function.
• •18\. Patients with decreased platelet.